Stryker Hips — Net Sales decreased by 1.9% to $914.00M in Q3 2025 compared to the prior quarter. Year-over-year, this metric grew by 8.8%, from $840.00M to $914.00M. Over 3 years (FY 2021 to FY 2024), Hips — Net Sales shows an upward trend with a 8.3% CAGR. This decline may warrant attention — for this metric, higher values are generally preferred.
An increase indicates growing market share or higher procedure volumes in hip arthroplasty, while a decrease may signal increased competition, pricing pressure, or a slowdown in elective orthopedic surgeries.
This metric represents the total revenue generated from the sale of hip reconstructive implants and related surgical ins...
Comparable to hip implant revenue segments reported by major orthopedic competitors like Zimmer Biomet or DePuy Synthes.
syk_segment_hips_net_sales| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $706.00M | $656.00M | $704.00M | $654.00M | $728.00M | $694.00M | $750.00M | $750.00M | $786.00M | $724.00M | $828.00M | $786.00M | $856.00M | $840.00M | $926.00M | $886.00M | $932.00M | $914.00M |
| QoQ Change | — | -7.1% | +7.3% | -7.1% | +11.3% | -4.7% | +8.1% | +0.0% | +4.8% | -7.9% | +14.4% | -5.1% | +8.9% | -1.9% | +10.2% | -4.3% | +5.2% | -1.9% |
| YoY Change | — | — | — | — | +3.1% | +5.8% | +6.5% | +14.7% | +8.0% | +4.3% | +10.4% | +4.8% | +8.9% | +16.0% | +11.8% | +12.7% | +8.9% | +8.8% |
We use cookies for analytics. See our Privacy and Cookie Policy.